POSTERS ESMO 2024

Cáncer de pulmón

No microcítico metastásico

Osimertinib versus first/second generation tyrosine kinase inhibitors as first line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: overall survival using real world data from TrinetX platform

Osimertinib versus first/second generation tyrosine kinase inhibitors as first line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: overall survival using real world data from TrinetX platform

Poster Bd #: 1274P

Poster

Descargar poster

Autor
Lisardo Ugidos De la Varga

Hospital Universitario Vithas Madrid

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON